Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artificial bear bile capsule is a pharmaceutical product developed as a synthetic alternative to natural bear bile (Xiongdan), which is traditionally used in Chinese medicine for its heat-clearing and detoxifying properties. Developed by the Institute of Materia Medica, Chinese Academy of Medical Sciences (IMM CAMS) in collaboration with Zhongshan Anshi Pharmaceutical, this formulation is designed to mimic the chemical composition and therapeutic efficacy of natural bear bile. It typically contains key bile acids such as ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA), or their taurine conjugates. The drug is currently being evaluated in Phase 3 clinical trials for the treatment of acute pharyngitis, specifically targeting patients with the "liver and stomach constrained heat" pattern in Traditional Chinese Medicine (TCM).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artificial bear bile capsule.